Key result
Between 1990 and 2017, the age-standardized prevalence rate of nonrheumatic valvular heart diseases in Iran increased by 15%, the death rate by 15.3%, and DALYs by 2%.
Why the study?
Nonrheumatic valvular heart diseases are common and treatable cardiovascular diseases, but their burden in Iran needed to be described and compared with global and regional data.
Observational (n=174,071)
Yes
The burden of nonrheumatic valvular heart diseases, including prevalence, death rate, and DALYs, increased in Iran between 1990 and 2017, contrasting with global and regional trends.
NRVD burden estimates in Iran inform regional planning; leaves open need for causal studies and targeted interventions.
Background: Nonrheumatic valvular heart diseases (NRVDs) are some of the common and treatable cardiovascular diseases. The objective of this study was to describe the burden of NRVDs in Iran from 1990 to 2017 and to compare the findings with those from the world and in particular, the North Africa and Middle East (NAME) region. Methods: Using publicly available estimates from the Global Burden of Disease 2017 Study (the GBD 2017 Study) for Iran and the NAME region, we reported the years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life years (DALYs), and the prevalence for NRVDs by age group and sex between 1990 and 2017. Results: There were an estimated 174,071 cases and 957 deaths from NRVDs in Iran in 2017. In addition, 1844 YLDs, 21,661 YLLs, and 23,506 DALYs were caused by NRVDs in Iran in 2017. Between 1990 and 2017, the age-standardized prevalence rate increased in Ian by 15%, the death rate by 15.3%, and DALYs by 2%. Nevertheless, in the world and the NAME region, the age-standardized rates for DALYs and deaths decreased and the age-standardized prevalence rate increased till 2017. Conclusions: The burden of NRVDs is on the rise in Iran. A reduction in the burden of NRVDs in Iran requires the development of appropriate plans to meet the health needs of patients, the decrease of the modifiable risk factors, the allocation of adequate resources for the early diagnosis and management of the diseases, and an improvement in access to treatment technologies.
No takes yet. Share an insight, caveat, or question.
Arabloo et al. (2022) conducted an observational in Nonrheumatic valvular heart diseases (n=174,071). Nonrheumatic valvular heart diseases was evaluated on Burden of NRVDs (YLLs, YLDs, DALYs, prevalence, and death rate). Between 1990 and 2017, the age-standardized prevalence rate of nonrheumatic valvular heart diseases in Iran increased by 15%, the death rate by 15.3%, and DALYs by 2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: